Clinical Study
Twice-Daily versus Once-Daily Pramipexole Extended Release Dosage Regimens in Parkinson’s Disease
Table 2
Dose switches from conventional dopaminergic agonist to pramipexole ER.
| Pramipexole IR pramipexole ER | Ropinirole pramipexole ER | Pramipexole IR daily dose, mg | Pramipexole ER, mg | Ropinirole daily dose, mg | Pramipexole ER, mg | Once-daily | Twice-daily | Once-daily | Twice-daily |
| 0.7 ≤ pramipexole < 0.8 | 0.75 | 0.375-0.375 | 3.0 ≤ ropinirole < 4.0 | 0.75 | 0.375-0.375 | 0.8 ≤ pramipexole < 1.1 | 1.125 | 0.75-0.375 | 4.0 ≤ ropinirole < 7.0 | 1.125 | 0.75-0.375 | 1.1 ≤ pramipexole < 1.6 | 1.5 | 0.75-0.75 | 7.0 ≤ ropinirole < 8.0 | 1.5 | 0.75-0.75 | 1.6 ≤ pramipexole < 1.9 | 1.875 | 1.125-0.75 | 8.0 ≤ ropinirole < 10.0 | 1.875 | 1.125-0.75 | 1.9 ≤ pramipexole < 2.3 | 2.25 | 1.125-1.125 | 10.0 ≤ ropinirole < 12.0 | 2.25 | 1.125-1.125 | 2.3 ≤ pramipexole < 2.7 | 2.625 | 1.5-1.125 | 12.0 ≤ ropinirole < 14.0 | 2.625 | 1.5-1.125 | 2.7 ≤ pramipexole < 3.1 | 3.0 | 1.5-1.5 | 14.0 ≤ ropinirole < 16.0 | 3.0 | 1.5-1.5 | 3.1 ≤ pramipexole < 3.4 | 3.375 | 1.875-1.5 | 16.0 ≤ ropinirole < 17.0 | 3.375 | 1.875-1.5 | 3.4 ≤ pramipexole < 3.8 | 3.75 | 1.875-1.875 | 17.0 ≤ ropinirole < 19.0 | 3.75 | 1.875-1.875 | 3.8 ≤ pramipexole < 4.2 | 4.125 | 2.25-1.875 | 19.0 ≤ ropinirole < 21.0 | 4.125 | 2.25-1.875 | 4.2 ≤ pramipexole < 4.6 | 4.5 | 2.25-2.25 | 21.0 ≤ ropinirole < 23.0 | 4.5 | 2.25-2.25 | 4.6 ≤ pramipexole < 4.9 | 4.875 | 2.625-2.25 | 23.0 ≤ ropinirole < 25.0 | 4.875 | 2.625-2.25 |
|
|
IR, immediate-release; ER, extended-release.
|